Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo

Journal of Virology

Volumn 88, Issue 1, 2014, Pages 763-767

  Abdel Mohsen, Mohamed ^a,d   Deng, Xutao ^b   Liegler, Teri ^a   Guatelli, John C ^c,d   Salama, Mohamed S ^e   Ghanem, Hussam El din A ^e   Rauch, Andri ^f   Ledergerber, Bruno ^g   Deeks, Steven G ^a   Günthard, Huldrych F ^g   Wong, Joseph K ^a,h   Pillai, Satish K ^a,b,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e Ain Shams University   (Egypt)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; INTERFERON ALPHA PLUS RIBAVIRIN; MEMBRANE PROTEIN; PROTEIN HERC5; PROTEIN IFITM1; PROTEIN IFITM2; PROTEIN IFITM3; PROTEIN ISG15; PROTEIN MOV10; PROTEIN PKR; TETHERIN; TRIPARTITE MOTIF PROTEIN 11; TRIPARTITE MOTIF PROTEIN 14; TRIPARTITE MOTIF PROTEIN 19; TRIPARTITE MOTIF PROTEIN 22; TRIPARTITE MOTIF PROTEIN 28; TRIPARTITE MOTIF PROTEIN 32; UNCLASSIFIED DRUG; VIPERIN;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENETIC ALGORITHM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; INNATE IMMUNITY; LONGITUDINAL STUDY; LYMPHOCYTE ACTIVATION; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION SITE; VIRUS LOAD; VIRUS REPLICATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

HIV; INTERFERON-ALPHA; RIBAVIRIN; VIRUS REPLICATION;

EID: 84890878887     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02687-13     Document Type: Article

References (22)

1. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147:258-267. http://dx.doi.org/10.1098/rspb .1957.0048.
2. Stetson DB, Medzhitov R. 2006. Type I interferons in host defense. Immunity 25:373-381. http://dx.doi.org/10.1016/j.immuni.2006.08.007.
3. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. 1989. Interferon-a but not AZT suppresses HIV expression in chronically infected cell lines. Science 244:575-577. http://dx.doi.org/10.1126/science.2470148.
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. 2004. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351:438-450. http: //dx.doi.org/10.1056/NEJMoa040842.
5. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. 2007. Antiretroviral activity of pegylated interferon alfa-2a in patients coinfected with HIV/hepatitis C virus. J. Antimicrob. Chemother. 59:565- 568. http://dx.doi.org/10.1093/jac/dkl497.
6. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Gunthard HF, Wong JK. 2012. Role of retroviral restriction factors in the interferonalpha-mediated suppression of HIV-1 in vivo. Proc. Natl. Acad. Sci. U. S. A. 109:3035-3040. http://dx.doi.org/10.1073/pnas.1111573109.
7. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB. 2010. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J. Infect. Dis. 201:1686-1696. http://dx.doi.org/10.1086/652420.
8. Hubbard JJ, Greenwell-Wild T, Barrett L, Yang J, Lempicki RA, Wahl SM, Asmuth DM, Murphy RL, Pollard RB, Kottilil S. 2012. Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a. J. Infect. Dis. 205:1443-1447. http://dx.doi.org/10.1093/infdis/jis211.
9. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ. 2013. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J. Infect. Dis. 207:213- 222. http://dx.doi.org/10.1093/infdis/jis663.
10. Neil S, Bieniasz P. 2009. Human immunodeficiency virus, restriction factors, and interferon. J. Interferon Cytokine Res. 29:569-580. http://dx .doi.org/10.1089/jir.2009.0077.
11. Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, Salama MS, Ghanem HE, Hoh R, Wong JK, David M, Nixon DF, Deeks SG, Pillai SK. 2013. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 10:106. http://dx.doi.org/10.1186/1742 -4690-10-106.
12. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, Telenti A, Furrer H, Yerly S, Francioli P. 2010. Cohort profile: the Swiss HIV Cohort study. Int. J. Epidemiol. 39:1179-1189. http://dx.doi.org/10.1093/ije/dyp321.
13. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3:RESEARCH0034. http://dx.doi.org/10.1186/gb-2002-3-7-research0034.
14. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:207-211. http://dx.doi.org/10.1126/science.1235214.
15. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340: 202-207. http://dx.doi.org/10.1126/science.1235208.
16. García-Arriaza J, Arnáez P, Gómez CE, Sorzano CO, Esteban M. 2013. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS One 8:e66894. http://dx.doi.org/10.1371/journal.pone.0066894.
17. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L. 2010. Interferonalpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 24:1415-1423. http://dx.doi.org/10.1097/QAD.0b013e32833ac623.
18. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Gunthard HF, Goldstein DB, Telenti A, Swiss HIVCS, Center for HIVAVI. 2010. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog. 6:e1000781. http://dx.doi.org/10.1371/journal.ppat.1000781.
19. Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, Harding CV. 2013. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 8:e56527. http://dx.doi.org/10.1371/journal.pone.0056527.
20. Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT, Pollard R, Asmuth D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM. 2012. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One 7:e30306. http://dx.doi.org/10.1371/journal.pone.0030306.
21. Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori D, Nixon DF, Pillai SK. 21 August 2013. Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J. Virol. http://dx.doi.org/10.1128/JVI.02128-13.
22. Raposo RA, Abdel-Mohsen M, Holditch SJ, Kuebler PJ, Cheng RG, Eriksson EM, Liao W, Pillai SK, Nixon DF. 2013. Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. J. Leukoc. Biol. [Epub ahead of print.] http://dx.doi.org/10.1189/jlb.0313150.